

Announcement No. 47/2008

To NASDAQ OMX Copenhagen A/S and the press

Copenhagen, 19 December 2008

**Report regarding the managements' and closely related parties' transactions with securities in Exiqon A/S**

Pursuant to section 28a of the Danish Securities Trading Act, Exiqon A/S is required to publish the managements' and their closely related parties' transactions with shares and related securities in Exiqon A/S.

Name:	Per Wold-Olsen
Reason for reporting:	Member of Exiqon's Board of Directors
Security Code (ISIN-kode):	DK0060077758
Name of the securities:	Share
Type of transaction:	Buy
Date of trade	December 18, 2008
Place of transaction:	NASDAQ OMX Copenhagen A/S
Traded securities (no.):	10.000
Market value in DKK of traded securities:	209.000

**Additional information**

CEO Lars Kongsbak, tlf. +45 45 66 08 88 or +45 40 90 21 01

CFO Hans Henrik Chrois Christensen tlf. +45 45 66 08 88 or +45 40 90 21 31

**About Exiqon**

Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyse the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqons new molecular diagnostic products are based on the LNA™ technology that

enables testing on fixed tissue. The first molecular diagnostic product was launched in December 2008. A number of new products will follow in the years ahead. Using the LNA™ technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

**Disclaimer**

Forward-looking statements:

This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.